SCHEMBL1625637

SCHEMBL1625637

CCOC(=O)C1=C(O)c2ccc(Br)cc2C(C)(C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.41
SMAD3 P84022 2/20 0.41
APAF1 O14727 1/20 0.41
SPR P35270 1/20 0.40
MAPT P10636 5/20 0.40
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRB2 P47870 1/20 0.39
KDM1A O60341 1/20 0.39
ALOX5 P09917 4/20 0.39
PTGES O14684 1/20 0.39
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
LMNA P02545 3/20 0.38
ESR1 P03372 1/20 0.38
ATM Q13315 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
PKM P14618 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1627014 0.90 SPR (0.45) TDP2SMAD3APAF1SPRMAPT
SCHEMBL1626913 0.85 SPR (0.52) SPRMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL1626427 0.85 KMT2A (0.42) SPRMAPTALOX5ALDH1A1SMN1; SMN2
SCHEMBL1626423 0.82 ALOX5 (0.39) SPRMAPTALOX5ALDH1A1KDM4E
SCHEMBL1626562 0.82 MAPT (0.48) TDP2APAF1SPRMAPTALDH1A1
SCHEMBL1625402 0.80 SPR (0.46) SPRMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL1625783 0.80 SPR (0.46) SPRMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL1626117 0.80 SPR (0.41) SPRMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL1626468 0.78 SPR (0.59) SPRMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL1627735 0.78 KDM5A (0.41) SPRMAPTALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN TDP2 3720/4885SMAD3 1724/4885APAF1 1377/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN TDP2 3720/4885SMAD3 1724/4885APAF1 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.